Rhodiola: what the research does and doesn't show

The label says "stress support", the next one says "energy", a third says "focus", and rhodiola is on all of them. It's a root with a good backstory and a very flexible job description. The interesting part is that "tired", "stressed", "can't concentrate" and "trains harder" are four different questions, and the research answers each of them with a different level of confidence. So let's pull them apart.

Here's where the research stands. Rhodiola has been tested in people for fatigue, stress, mental performance and exercise. Some small trials of specific branded extracts found improvements, one placebo-controlled trial found the opposite, and the systematic reviews describe the evidence as promising but patchy. The US National Center for Complementary and Integrative Health (NCCIH, updated April 2025) puts it plainly: there isn't enough reliable evidence to determine whether rhodiola is useful for any health-related purpose.

Four questions, four levels of confidence

• What people hope for: Less tiredness and mental fatigue; What the trials actually looked at: Small trials in stressed or sleep-deprived groups (cadets, students, doctors on night duty) and in people with burnout-type fatigue; How firm it looks: Some positive results, one placebo-controlled reversal, and reviews that flag weak methods
• What people hope for: Lower stress, better mood; What the trials actually looked at: Mildly anxious or stressed adults; one trial in people with diagnosed depression; How firm it looks: Encouraging, but mostly from designs without a placebo
• What people hope for: Sharper concentration and reaction time; What the trials actually looked at: A handful of small trials with different tests; How firm it looks: Thin
• What people hope for: Better physical performance; What the trials actually looked at: Many small exercise trials; How firm it looks: Mixed but leaning positive; it says little about mental work

A root with several names

Rhodiola rosea is a plant that grows in cold, high-altitude regions of Europe, Asia and North America. You'll also see it sold as arctic root, golden root or rose root (the Dutch name in European regulatory documents is rozewortel). The part used is the root and rhizome. NCCIH notes it was historically used in Russia and Scandinavia for work performance and fatigue, which is a fair description of why it ended up in the stress-and-energy aisle.

"Adaptogen" is the word that usually follows it. It's a traditional and marketing category rather than something a trial can measure, so this page sticks to outcomes that were actually measured.

Two compound groups do most of the talking on labels: rosavins and salidroside. Rosavins are specific to R. rosea, while salidroside also turns up in other Rhodiola species, and in the plant the two occur at roughly a 3:1 ratio (Punja et al. 2014). That matters because "rhodiola" on a pack can mean more than one species. A 2021 review of 39 randomised trials included 23 on R. rosea and others on R. crenulata and R. wallichiana (Li et al. 2021), and findings from one species shouldn't be assumed for another.

Which extract was in the trial?

Almost every positive result comes from a specific, named extract rather than from "rhodiola" in general. Think of it like testing one particular recipe and then assuming every soup tastes the same:

• Extract as named in the study: SHR-5; Trials mentioned on this page: Darbinyan 2000, Spasov 2000, Shevtsov 2003, Olsson 2009
• Extract as named in the study: WS 1375; Trials mentioned on this page: Edwards 2012, Lekomtseva 2017, Koop 2020
• Extract as named in the study: A tablet product called Vitano; Trials mentioned on this page: Cropley 2015
• Extract as named in the study: Extract standardised to 2.8% total rosavins; Trials mentioned on this page: Punja 2014

Extract identity has regulatory consequences too. When a company asked the European Food Safety Authority (EFSA) to assess a "reduces mental fatigue" claim for a rhodiola extract standardised for both rosavins and salidroside, the panel noted that the two studies offered had used an extract standardised only for salidroside, and concluded that no cause-and-effect relationship had been established for that claim (EFSA, 2012). It's a claim-specific opinion about one application, not a verdict on the whole plant, but it shows why "the studied extract" and "the extract in your capsule" aren't automatically the same thing.

Fatigue and mental performance

The oldest and most-quoted trials used SHR-5:

• Doctors on night duty. 56 young physicians took part in a double-blind crossover trial. The group taking rhodiola scored better on mental-performance tests in the first two-week period (Darbinyan et al. 2000).
• Students at exam time. A 20-day placebo-controlled pilot found improvements in physical fitness, mental fatigue and neuro-motor tests; the authors thought the dose was probably too low (Spasov et al. 2000).
• Cadets. In 161 cadets aged 19 to 21, a single dose gave a higher "anti-fatigue index" than placebo, with no clear difference between the two doses tested (Shevtsov et al. 2003).
• Stress-related fatigue syndrome. In 60 people meeting Swedish diagnostic criteria, 576 mg a day of SHR-5 for 28 days was compared with placebo. Both groups improved, but the extract did better on a burnout scale and on some attention measures (Olsson et al. 2009).

Those are the good-news trials. Several of the older ones are small, short and from the same extract family.

Then there's the plot twist. In a double-blind trial of 48 nursing students on shift work, a 42-day course of 364 mg rhodiola (with the option of a second capsule within four hours) left fatigue scores worse than placebo, and the authors urged caution because the study fell short of its planned size (Punja et al. 2014). The trial was funded by an Alberta government-backed body, which also prepared the product. One trial can't overrule the others, but it was placebo-controlled, it studied everyday work-related fatigue, and it didn't favour rhodiola.

Open-label studies, where everyone knows they're taking the extract, report improvements too: 100 people with prolonged fatigue taking 2 × 200 mg WS 1375 for eight weeks (Lekomtseva et al. 2017) and 101 people with life-stress symptoms over four weeks (Edwards et al. 2012). Without a control group those results can't separate the extract from expectation and from people simply feeling better with time.

What do the reviews say? A 2011 systematic review of 11 placebo-controlled trials found that most were of moderate or good quality and concluded rhodiola may have beneficial effects, but flagged a lack of independent replication (Hung et al. 2011). A 2012 review of 11 studies on physical and mental fatigue judged all of them to be at high or unclear risk of bias and called the research "contradictory" (Ishaque et al. 2012).

Stress, mood and anxiety

A 2015 trial gave 80 mildly anxious adults 2 × 200 mg of an extract daily for 14 days. They reported lower anxiety, stress, anger, confusion and depression than a comparison group, with no difference on the cognitive tests (Cropley et al. 2015). The comparison group received no treatment rather than a placebo, the authors say they can't determine causality, and Europe PMC lists Dr Willmar Schwabe as a funder of the trial.

The 2012 WS 1375 study above was open-label as well. So the stress evidence, like the fatigue evidence, rests more on promising designs than on strong ones.

There is one placebo-controlled trial in people with diagnosed mild to moderate depression: 57 adults took rhodiola extract, sertraline or placebo for 12 weeks, and the three groups did not differ significantly on the main scales. Fewer people on rhodiola (30%) reported adverse events than on sertraline (63.2%) (Mao et al. 2015). It's a small proof-of-concept study rather than a reason to change treatment, and anyone feeling low for weeks should talk to a GP rather than a supplement shelf.

Concentration, reaction time and the gaming question

If you're here because of gaming, this is the part that matters, and it's short.

• In 26 healthy male students, 600 mg a day for four weeks shortened reaction times in simple and choice psychomotor tests compared with placebo, with no change in endurance capacity (Jówko et al. 2018).
• In 50 adults taking 2 × 200 mg WS 1375 for 12 weeks, reaction times improved on attention tasks, but the study was single-arm and open-label, and the authors say a double-blind placebo-controlled trial is needed (Koop et al. 2020).
• The 80-person anxiety trial found no cognitive differences between groups (see above).

None of the trials above measured gaming or esports performance. Reaction-time tests are a reasonable cousin of that question, but a lab test in 26 students isn't a ranked match, so rhodiola as a proven "gamer focus" ingredient would be a stretch.

Physical performance, briefly

Rhodiola has by far the most trials in exercise settings. A 2023 systematic review of 13 randomised trials (263 participants) found mostly positive but heterogeneous results and unclear or high risk of bias in most studies (Sanz-Barrio et al. 2023). A 2025 meta-analysis of 26 randomised trials in 668 healthy participants concluded it improved endurance-related outcomes, with heterogeneity that "warrants cautious interpretation" (Wang et al. 2025). Those findings concern sport. They don't transfer to mental work, and the reverse is also true.

Side effects, interactions and who should sit this one out

• Side effects. NCCIH lists dizziness, headache, insomnia, and dry mouth or excessive saliva and says rhodiola is "possibly safe" for up to 12 weeks. The European Medicines Agency's monograph (below) lists headache, nausea, abdominal pain, diarrhoea, skin rash and itching, with frequency unknown.
• Medicines. NCCIH notes that an interaction with losartan, a blood-pressure medicine, has been reported. A 2015 case report describes a 68-year-old woman who developed restlessness and trembling after adding rhodiola to paroxetine, which the authors read as a possible serotonin-related reaction (Maniscalco et al. 2015). One case can't tell us how common that is. The EMA, for its part, states that no clinically relevant interactions have been observed. Good evidence on combining rhodiola with stimulants such as caffeine is lacking, so "unknown" is the honest answer there. If you take prescription medication, our guide to supplements and medication is a sensible next stop.
• Pregnancy, breastfeeding and under-18s. The EMA says safety in pregnancy and lactation has not been established and use is not recommended, and that use under 18 is not recommended. NCCIH says little is known about use in pregnancy or breastfeeding.
• Product quality. A 2026 analysis of a small sample of rhodiola supplements sold in the US found rosavin levels from 0.01% to 3.08% and salidroside from 0.07% to 2.91%, with substantial gaps from advertised amounts, one product with a likely undisclosed addition of synthetic salidroside, and trace heavy metals in all seven capsule products tested (Porwollik & Jafari 2026). It was a small US sample and says nothing about any particular European product, but it's a fair reason to read labels carefully.

Rhodiola under EU and Dutch rules

Dated 8 October 2026; rules change, so check current wording before relying on it.

• As a medicine. The EMA's herbal committee (HMPC) adopted a revised EU herbal monograph for Rhodiola rosea root and rhizome on 20 March 2024. It covers dry extract (drug-to-extract ratio 1.5 to 5:1, extracted with 67 to 70% ethanol) as a traditional herbal medicinal product for the relief of symptoms of stress, such as fatigue and exhaustion, 144 to 400 mg a day for adults, and advises seeing a doctor if symptoms persist beyond two weeks. "Traditional use" means the indication rests on long-standing use rather than on clinical-trial proof, and the monograph is guidance for licensed medicines, not for food supplements.
• In the Netherlands. The Dutch herbal-preparations decree (Warenwetbesluit Kruidenpreparaten) has an annex listing plants and fungi that herbal preparations must not contain (Article 4(2); it names kava and yohimbe, for example). Rhodiola is not named there, but that is not an approval: other rules, including EU novel-food law, are separate (wetten.overheid.nl, version in force from 1 July 2022 as shown on 8 October 2026). A January 2026 draft amendment to the decree exists, and its text was not opened, so don't treat the annex as final.
• EU food rules. We couldn't confirm the EU novel-food status of rhodiola, so we make no statement about it. Check the Commission's Novel Food Status Catalogue before buying.

Decoding a rhodiola label

Here's an invented label, purely for illustration:

Rhodiola rosea root extract, 400 mg per capsule, standardised to 3% rosavins and 1% salidroside.

• Species: it says Rhodiola rosea, which is what most of the research above used. A label that says only "Rhodiola" isn't specific enough.
• Extract or powder: "extract" with a standardisation is the closer match to the trials. A ground root powder is a different thing.
• Marker content: 3% of 400 mg is up to 12 mg of rosavins and 1% is up to 4 mg of salidroside per capsule. That's simple arithmetic from the label, and it's useful mainly for comparing products with each other.
• Dose against the research: the trials above that report an amount used roughly 364 to 600 mg of extract a day (several used 2 × 200 mg), in different extracts, and the EMA's traditional-use range is 144 to 400 mg a day. Those are descriptions of what was studied, not instructions. Different extracts aren't interchangeable milligram for milligram.
• Quality: given the Porwollik findings, a batch test result or certificate of analysis is worth looking for. Our guide to reading supplement labels covers the general method.

Rhodiola so far: a good CV and an unfinished file

Rhodiola is an interesting ingredient with an unfinished evidence file. It has a traditional-use status in EU medicine, a body of small trials on named extracts, and reviews that keep asking for bigger, better-reported, independent studies. For mental fatigue and stress the signals are encouraging but mostly come from weak designs, and the best-controlled everyday-fatigue trial went against it. For concentration the data are thin, and for gaming specifically the trials above don't reach it. If rhodiola caught your eye, the useful questions are which species and extract a product contains, and what the trials behind that extract actually measured.

If supplements in general are new territory, our beginner's guide is a gentle place to begin.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.